ITI-007 (Lumateperone Tosylate) for Schizophrenia

Patients will be started on ITI-007 and current medication will be slowly discontinued within
the first 7 days of starting ITI-007, with some flexibility allowed if clinically indicated.
No patients will be left unmedicated because of this study.

Patients will be seen weekly for the first 4 weeks, biweekly for the second month and then
monthly for six months. Patients will be monitored by clinical and safety rating scales, and
will be required to show improvement after 3 months to remain in this study. Patients not
improving at this time will be assessed for the risks/benefits of continuing.

Inclusion Criteria:

- Diagnostic and Statistical Manual of Mental Disorders, 5th edition (DSM-5) diagnosis
of schizophrenia or schizoaffective disorder

- Has capacity to provide informed consent

- Medically stable for study participation

- Judged clinically not to be at significant suicide or violence risk

- Inadequate response or tolerability to previously antipsychotic therapy, as defined by
at least one of the following: prior clozapine failure, a PANSS>80 despite at least
six weeks of a current antipsychotic therapy, a Clinical Global Impressions
scale-Improvement (CGI-I) of 4 after at least two six week trials of antipsychotics
(retrospective assessment) or failure to tolerate an adequate dose of at least
antipsychotics (as defined by the Physicians Desk Reference)

Exclusion Criteria:

- Substance abuse within last 90 days

- ECG abnormality that is clinically significant

- Pregnancy, lactation, or lack of use of effective birth control

- Presence or positive history of significant unstable medical or neurological illness
(including any history of seizure disorder, hepatitis, renal insufficiency or mental
retardation), history of HIV

- Clinically significant abnormal laboratory tests, positive for hepatitis B or C or
liver function tests (LFTs) > 2x Upper Limit of Normal, use of strong CYP3A4
inhibitors or inducers

- History or presence of concomitant major psychiatric illness.

- Use of other antipsychotic medications at baseline.

- Use of another investigational medication in the previous 4 weeks